Switching from tamoxifen to aromatase inhibitors for adjuvant endocrine therapy in postmenopausal patients with early breast cancer

2010 ◽  
Vol 36 (1) ◽  
pp. 54-62 ◽  
Author(s):  
C.J.H. van de Velde ◽  
S. Verma ◽  
J.G.H. van Nes ◽  
C. Masterman ◽  
K.I. Pritchard
Keyword(s):  
Breast Cancer ◽  
Endocrine Therapy ◽  
Early Breast Cancer ◽  
Aromatase Inhibitors ◽  
Adjuvant Endocrine Therapy

Cardiovascular Adverse Events During Adjuvant Endocrine Therapy for Early Breast Cancer Using Letrozole or Tamoxifen: Safety Analysis of BIG 1-98 Trial

2007 ◽  
Vol 25 (36) ◽  
pp. 5715-5722 ◽  
Author(s):  
Henning Mouridsen ◽  
Aparna Keshaviah ◽  
Alan S. Coates ◽  
Manuela Rabaglio ◽  
Monica Castiglione-Gertsch ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Adverse Events ◽  
Endocrine Therapy ◽  
Early Breast Cancer ◽  
Aromatase Inhibitors ◽  
Safety Analysis ◽  
Adjuvant Endocrine Therapy ◽  
Double Blind ◽  
Significant Difference ◽  
Grade 3

Purpose Previous analyses of adjuvant studies of aromatase inhibitors versus tamoxifen, including the Breast International Group (BIG) 1-98 study, have suggested a small numerical excess of cardiac adverse events (AEs) on aromatase inhibitors, a reduction in the incidence of hypercholesterolemia on tamoxifen, and significantly higher incidence of thromboembolic AEs on tamoxifen. The purpose of the present study is to provide detailed updated information on these AEs in BIG 1-98. Patients and Methods Eight thousand twenty-eight postmenopausal women with receptor-positive early breast cancer were randomly assigned (double-blind) between March 1998 and May 2003 to receive 5 years of adjuvant endocrine therapy with letrozole, tamoxifen, or a sequence of these agents. Seven thousand nine hundred sixty-three patients who actually received therapy are included in this safety analysis, which focuses on cardiovascular events. AE recording ceased 30 days after therapy completion (or after switch on the sequential arms). Results Baseline comorbidities were balanced. At a median follow-up time of 30.1 months, we observed similar overall incidence of cardiac AEs (letrozole, 4.8%; tamoxifen, 4.7%), more grade 3 to 5 cardiac AEs on letrozole (letrozole, 2.4%; tamoxifen, 1.4%; P = .001)—an excess only partially attributable to prior hypercholesterolemia—and more overall (tamoxifen, 3.9%; letrozole, 1.7%; P < .001) and grade 3 to 5 thromboembolic AEs on tamoxifen (tamoxifen, 2.3%; letrozole, 0.9%; P < .001). There was no significant difference between tamoxifen and letrozole in incidence of hypertension or cerebrovascular events. Conclusion The present safety analysis, limited to cardiovascular AEs in BIG 1-98, documents a low overall incidence of cardiovascular AEs, which differed between treatment arms.

Extended adjuvant endocrine therapy in early breast cancer: a meta-analysis of published randomized trials

2017 ◽  
Vol 34 (7) ◽  
Author(s):  
Ezzeldin M. Ibrahim ◽  
Marwan R. Al-Hajeili ◽  
Ali M. Bayer ◽  
Omalkhair A. Abulkhair ◽  
Ahmed A. Refae
Keyword(s):  
Breast Cancer ◽  
Endocrine Therapy ◽  
Early Breast Cancer ◽  
Randomized Trials ◽  
Meta Analysis ◽  
Adjuvant Endocrine Therapy

The impact of adjuvant endocrine therapy in early breast cancer on quality-of-life: an overview of prospective trials

2016 ◽  
Vol 1 (2) ◽  
pp. 111-120 ◽  
Author(s):  
Eleonora Mioranza ◽  
Cristina Falci ◽  
Maria Vittoria Dieci ◽  
Valentina Guarneri ◽  
Pierfranco Conte
Keyword(s):  
Breast Cancer ◽  
Quality Of Life ◽  
Endocrine Therapy ◽  
Early Breast Cancer ◽  
Adjuvant Endocrine Therapy ◽  
Prospective Trials ◽  
The Impact
Sign in / Sign up

Export Citation Format

Share Document